Katkin Keith (CIK 1314596) reported 7 SEC Form 4 insider transactions across 3 companies over the past 18 months (most recent 2026-05-04). Recent activity: Sell EBS (15,481 shares), Buy EBS (25,344 shares), Buy SNDX (24,000 shares), Buy ELDN (8,575 shares), Sell EBS (7,844 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-04 | Emergent BioSolutions Inc. (EBS) | Director | Sell | 15,481 | $128,183 |
| 2026-05-04 | Emergent BioSolutions Inc. (EBS) | Director | Buy | 25,344 | $0 |
| 2026-02-06 | Syndax Pharmaceuticals Inc (SNDX) | Director | Buy | 24,000 | $0 |
| 2026-01-16 | Eledon Pharmaceuticals, Inc. (ELDN) | Director | Buy | 8,575 | $0 |
| 2025-05-28 | Emergent BioSolutions Inc. (EBS) | Director | Sell | 7,844 | $49,417 |
| 2025-05-19 | Syndax Pharmaceuticals Inc (SNDX) | Director | Buy | 10,000 | $91,100 |
| 2025-05-02 | Emergent BioSolutions Inc. (EBS) | Director | Buy | 34,403 | $0 |
Source: SEC Form 4 filings · as of 2026-05-04